Ryan P. Mynatt

1.5k total citations
37 papers, 1.1k citations indexed

About

Ryan P. Mynatt is a scholar working on Infectious Diseases, Pharmacology and Clinical Biochemistry. According to data from OpenAlex, Ryan P. Mynatt has authored 37 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Infectious Diseases, 17 papers in Pharmacology and 15 papers in Clinical Biochemistry. Recurrent topics in Ryan P. Mynatt's work include Antimicrobial Resistance in Staphylococcus (18 papers), Antibiotics Pharmacokinetics and Efficacy (17 papers) and Bacterial Identification and Susceptibility Testing (15 papers). Ryan P. Mynatt is often cited by papers focused on Antimicrobial Resistance in Staphylococcus (18 papers), Antibiotics Pharmacokinetics and Efficacy (17 papers) and Bacterial Identification and Susceptibility Testing (15 papers). Ryan P. Mynatt collaborates with scholars based in United States, Canada and Israel. Ryan P. Mynatt's co-authors include Jason M. Pogue, Michael J. Rybak, Kyle P. Murray, Evan J Zasowski, Keith S. Kaye, Natalie A. Finch, Trang D Trinh, Jing Zhao, Raymond Yost and Susan L. Davis and has published in prestigious journals such as Clinical Infectious Diseases, Antimicrobial Agents and Chemotherapy and Critical Care Medicine.

In The Last Decade

Ryan P. Mynatt

33 papers receiving 1.1k citations

Peers

Countries citing papers authored by Ryan P. Mynatt

Since Specialization

Citations

This map shows the geographic impact of Ryan P. Mynatt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryan P. Mynatt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryan P. Mynatt more than expected).

Fields of papers citing papers by Ryan P. Mynatt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryan P. Mynatt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryan P. Mynatt. The network helps show where Ryan P. Mynatt may publish in the future.

Co-authorship network of co-authors of Ryan P. Mynatt

This figure shows the co-authorship network connecting the top 25 collaborators of Ryan P. Mynatt. A scholar is included among the top collaborators of Ryan P. Mynatt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ryan P. Mynatt. Ryan P. Mynatt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	P-1878. Intravenous Ganciclovir Administration Outcomes via an Outpatient Parenteral Antimicrobial Therapy (OPAT) Program 2025 ·Open Forum Infectious Diseases ·(unknown), Ryan P. Mynatt, (unknown), (unknown), (unknown)	0
2	Performance of ePlex® blood culture identification panels in clinical isolates and characterization of antimicrobial stewardship opportunities 2024 ·Diagnostic Microbiology and Infectious Disease ·(unknown), (unknown), Vaneet Arora, David S. Burgess, Donna R. Burgess, Ryan P. Mynatt, (unknown), (unknown), (unknown)	4
3	Antibiotics for Patients With a Planned Re-Laparotomy for Intra-Abdominal Infection 2024 ·Surgical Infections ·(unknown), (unknown), Jacqueline M. Bishop, (unknown), (unknown), Ryan P. Mynatt, (unknown), Aric Schadler, Sara E. Parli	0
4	Candidemia Surveillance and Impact on Non-neutropenic Critically Ill Patients 2024 ·Cureus ·Lisa Hall Zimmerman, (unknown), (unknown), Linda Park, Ryan P. Mynatt, (unknown), Alfred E. Baylor, James G. Tyburski, Robert F. Wilson	0
5	Antimicrobial Stewardship Practices in Outpatient Parenteral Antimicrobial Therapy Programs in the United States 2024 ·Open Forum Infectious Diseases ·(unknown), (unknown), Ryan P. Mynatt, Donna R. Burgess, (unknown), Rebekah Wrenn, (unknown), (unknown), (unknown), (unknown), Carla Walraven	0
6	Clinical Outcomes With Extended Versus Intermittent Infusion of Anti-Pseudomonal Beta-Lactams in Patients With Gram-Negative Bacteremia 2023 ·Open Forum Infectious Diseases ·(unknown), Ryan P. Mynatt, Keith S. Kaye, Jing Zhao, Jason M. Pogue	9
7	A review of evidence, antimicrobial stability, and feasibility considerations for OPAT continuous infusion 2023 ·Therapeutic Advances in Infectious Disease ·(unknown), Lindsey M. Childs‐Kean, (unknown), Ryan P. Mynatt, (unknown), Christina G. Rivera	2
8	Monotherapy with Vancomycin or Daptomycin versus Combination Therapy with β-Lactams in the Treatment of Methicillin-Resistant Staphylococcus Aureus Bloodstream Infections: A Retrospective Cohort Analysis 2020 ·Infectious Diseases and Therapy ·Sara Alosaimy, Noor Sabagha, Abdalhamid M Lagnf, Evan J Zasowski, Taylor Morrisette, Sarah C J Jorgensen, Trang D Trinh, Ryan P. Mynatt, Michael J. Rybak	23
9	Daptomycin Plus β-Lactam Combination Therapy for Methicillin-resistant Staphylococcus aureus Bloodstream Infections: A Retrospective, Comparative Cohort Study 2019 ·Clinical Infectious Diseases ·Sarah C J Jorgensen, Evan J Zasowski, Trang D Trinh, Abdalhamid M Lagnf, Sahil Bhatia, Noor Sabagha, Jacinda C. Abdul‐Mutakabbir, Sara Alosaimy, Ryan P. Mynatt, Susan L. Davis, Michael J. Rybak	72
10	2250. Combination Vancomycin Plus Cefazolin for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections 2019 ·Open Forum Infectious Diseases ·Sarah C J Jorgensen, Trang D Trinh, Evan J Zasowski, Sara Alosaimy, (unknown), Sahil Bhatia, Sorabh Dhar, Ryan P. Mynatt, Jason M. Pogue, Michael J. Rybak	6
11	Relationship Status between Vancomycin Loading Dose and Treatment Failure in Patients with MRSA Bacteremia: It’s Complicated 2019 ·Infectious Diseases and Therapy ·Jessica K. Ortwine, Evan J Zasowski, Jason M. Pogue, (unknown), (unknown), Anthony M. Casapao, Ryan P. Mynatt, Michael J. Rybak	11
12	Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin–Tazobactam Compared to Those on Vancomycin and Cefepime 2016 ·Clinical Infectious Diseases ·Bhagyashri Navalkele, Jason M. Pogue, (unknown), (unknown), Madiha Salim, Shantanu Solanki, (unknown), (unknown), (unknown), (unknown), (unknown), Tanveer Hussain, William Perry, Richard B. Evans, Emily T. Martin, Ryan P. Mynatt, Kyle P. Murray, Michael J. Rybak, Keith S. Kaye	137
13	Epidemiology of Acute Kidney Injury among Patients Receiving Concomitant Vancomycin and Piperacillin-Tazobactam: Opportunities for Antimicrobial Stewardship 2016 ·Antimicrobial Agents and Chemotherapy ·(unknown), Keith S. Kaye, Bhagyashri Navalkele, (unknown), Madiha Salim, Shantanu Solanki, (unknown), (unknown), (unknown), (unknown), Emily T. Martin, Ryan P. Mynatt, Kyle P. Murray, Michael J. Rybak, Jason M. Pogue	50
14	Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Pneumonia with Ceftaroline Fosamil in a Patient with Inhalational Thermal Injury 2015 ·Infectious Diseases and Therapy ·(unknown), Ryan P. Mynatt, (unknown), Michael J. Rybak	8
15	Large Retrospective Evaluation of the Effectiveness and Safety of Ceftaroline Fosamil Therapy 2014 ·Antimicrobial Agents and Chemotherapy ·Anthony M. Casapao, Susan L. Davis, (unknown), Kenneth Klinker, Debra A. Goff, Katie E. Barber, Keith S. Kaye, Ryan P. Mynatt, (unknown), Jason M. Pogue, Michael J. Rybak	96
16	Carbapenem-Resistance in Gram-Negative Bacilli and Intravenous Minocycline: An Antimicrobial Stewardship Approach at the Detroit Medical Center 2014 ·Clinical Infectious Diseases ·Jason M. Pogue, (unknown), Ryan P. Mynatt, Sarit Sharma, Paul Lephart, Keith S. Kaye	46
17	Bringing the "Power" to Cerner's PowerChart for Antimicrobial Stewardship 2014 ·Clinical Infectious Diseases ·Jason M. Pogue, Brian A. Potoski, Michael Postelnick, Ryan P. Mynatt, (unknown), Gregory Eschenauer, Keith S. Kaye	17
18	Automated Alerts Coupled with Antimicrobial Stewardship Intervention Lead to Decreases in Length of Stay in Patients with Gram-Negative Bacteremia 2013 ·Infection Control and Hospital Epidemiology ·Jason M. Pogue, Ryan P. Mynatt, Dror Marchaim, Jing Zhao, (unknown), Judy Moshos, Bharath Sunkara, Teena Chopra, (unknown), Keith S. Kaye	47
19	Fosfomycin activity versus carbapenem-resistant Enterobacteriaceae and vancomycin-resistant Enterococcus, Detroit, 2008–10 2013 ·The Journal of Antibiotics ·Jason M. Pogue, Dror Marchaim, Odaliz Abreu-Lanfranco, Bharath Sunkara, Ryan P. Mynatt, Jing Zhao, Suchitha Bheemreddy, Kayoko Hayakawa, Emily T. Martin, Sorabh Dhar, Keith S. Kaye, Paul Lephart	25
20	Extended-Spectrum β-Lactamase Producers Reported as Susceptible to Piperacillin-Tazobactam, Cefepime, and Cefuroxime in the Era of Lowered Breakpoints and No Confirmatory Tests 2012 ·Infection Control and Hospital Epidemiology ·Dror Marchaim, Bharath Sunkara, Paul Lephart, (unknown), Ashish Bhargava, Ryan P. Mynatt, Jing Zhao, Suchitha Bheemreddy, Kayoko Hayakawa, Teena Chopra, Sorabh Dhar, Keith S. Kaye	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact